Aerosol Delivery of Small Hairpin Osteopontin Blocks Pulmonary Metastasis of Breast Cancer in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Jan 5

PMID 21203518

Citations 7

Authors

Kyeong-Nam Yu

Arash Minai-Tehrani

Seung-Hee Chang

Soon-Kyung Hwang

Seong-Ho Hong

Ji-Eun Kim

Ji-Young Shin

Sung-Jin Park

Ji-Hye Kim

Jung-Taek Kwon

Hu-Lin Jiang

Bitna Kang

Duyeol Kim

Chan-Hee Chae

Kee-Ho Lee

Tae-Jong Yoon

George R Beck

Myung-Haing Cho

Affiliations

Soon will be listed here.

Abstract

Background: Metastasis to the lung may be the final step in the breast cancer-related morbidity. Conventional therapies such as chemotherapy and surgery are somewhat successful, however, metastasis-related breast cancer morbidity remains high. Thus, a novel approach to prevent breast tumor metastasis is needed.

Methodology/principal Finding: Aerosol of lentivirus-based small hairpin osteopontin was delivered into mice with breast cancer twice a week for 1 or 2 months using a nose-only inhalation system. The effects of small hairpin osteopontin on breast cancer metastasis to the lung were evaluated using near infrared imaging as well as diverse molecular techniques. Aerosol-delivered small hairpin osteopontin significantly decreased the expression level of osteopontin and altered the expression of several important metastasis-related proteins in our murine breast cancer model.

Conclusion/significance: Aerosol-delivered small hairpin osteopontin blocked breast cancer metastasis. Our results showed that noninvasive targeting of pulmonary osteopontin or other specific genes responsible for cancer metastasis could be used as an effective therapeutic regimen for the treatment of metastatic epithelial tumors.

Citing Articles

Focused targeting of inhaled magnetic aerosols in reconstructed in vitro airway models.

Ostrovski Y, Dorfman S, Poh W, Loo S, Sznitman J J Biomech. 2021; 118:110279.

PMID: 33545572 PMC: 7611795. DOI: 10.1016/j.jbiomech.2021.110279.

Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Sawyer A, Kyriakides T Adv Drug Deliv Rev. 2016; 97:56-68.

PMID: 26763408 PMC: 4753140. DOI: 10.1016/j.addr.2015.12.016.

Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein.

He H, Zhang M, Liu L, Zhang S, Liu J, Zhang W Pharm Res. 2015; 32(10):3415-31.

PMID: 26040661 DOI: 10.1007/s11095-015-1719-x.

Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.

Weber C, Kothari A, Wai P, Li N, Driver J, Zapf M Oncogene. 2014; 34(37):4821-33.

PMID: 25531323 PMC: 4476970. DOI: 10.1038/onc.2014.410.

Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Zarogouldis P, Karamanos N, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W Int J Mol Sci. 2012; 13(9):10828-10862.

PMID: 23109824 PMC: 3472716. DOI: 10.3390/ijms130910828.

References

Singhal H, Bautista D, Tonkin K, OMalley F, Tuck A, Chambers A . Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997; 3(4):605-11. View

Behrend E, Craig A, Wilson S, Denhardt D, Chambers A . Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 1994; 54(3):832-7. View

Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4):581-611. DOI: 10.1210/er.2003-0027. View

Denhardt D . Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog. 1996; 7(3-4):261-91. DOI: 10.1615/critrevoncog.v7.i3-4.70. View

Thaete L, Ahnen D, Malkinson A . Proliferating cell nuclear antigen (PCNA/cyclin) immunocytochemistry as a labeling index in mouse lung tissues. Cell Tissue Res. 1989; 256(1):167-73. DOI: 10.1007/BF00224731. View

Goula D, Becker N, Lemkine G, Normandie P, Rodrigues J, Mantero S . Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 2000; 7(6):499-504. DOI: 10.1038/sj.gt.3301113. View

Brown L, Berse B, Manseau E, Tognazzi K, Perruzzi C, Dvorak H . Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994; 145(3):610-23. PMC: 1890312. View

Gautam A, Densmore C, Golunski E, Xu B, Waldrep J . Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol Ther. 2001; 3(4):551-6. DOI: 10.1006/mthe.2001.0300. View

Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno N . Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010; 9(5):1180-7. DOI: 10.1158/1535-7163.MCT-09-1025. View

10.

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

11.

Adwan H, Bauerle T, Najajreh Y, Elazer V, Golomb G, Berger M . Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol. 2004; 24(5):1235-44. View

12.

Weber G, Lett G, Haubein N . Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6):861-9. PMC: 2966627. DOI: 10.1038/sj.bjc.6605834. View

13.

Vinh-Hung V, Verschraegen C, Promish D, Cserni G, Van De Steene J, Tai P . Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004; 6(6):R680-8. PMC: 1064081. DOI: 10.1186/bcr934. View

14.

Hwang S, Kwon J, Park S, Chang S, Lee E, Chung Y . Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther. 2007; 14(24):1721-30. DOI: 10.1038/sj.gt.3303042. View

15.

Kay M, Glorioso J, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001; 7(1):33-40. DOI: 10.1038/83324. View

16.

Lotze M, Kost T . Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther. 2002; 9(8):692-9. DOI: 10.1038/sj.cgt.7700493. View

17.

Suzuki H, Yamashiro K . Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer. 2002; 38(2):137-41. DOI: 10.1016/s0169-5002(02)00176-9. View

18.

Hwang S, Lim H, Minai-Tehrani A, Lee E, Park J, Park S . Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice. Am J Respir Crit Care Med. 2009; 179(12):1131-40. PMC: 5450614. DOI: 10.1164/rccm.200810-1553OC. View

19.

Shevde L, Das S, Clark D, Samant R . Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010; 10(1):71-81. PMC: 6869338. DOI: 10.2174/156652410791065381. View

20.

Paradis V, Eschwege P, Loric S, Dumas F, Ba N, Benoit G . De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol. 1999; 51(11):798-802. PMC: 500969. DOI: 10.1136/jcp.51.11.798. View